| 16th Sep 2022 7:00 am |
RNS |
Nirsevimab recommended for approval in EU by CHMP |
| 5th Sep 2022 7:05 am |
RNS |
Forxiga approved in China for CKD |
| 5th Sep 2022 7:00 am |
RNS |
Imfinzi approved in US for biliary tract cancer |
| 1st Sep 2022 3:00 pm |
RNS |
Total Voting Rights |
| 30th Aug 2022 1:00 pm |
RNS |
Evusheld approved for COVID-19 in Japan |
| 30th Aug 2022 7:01 am |
RNS |
Farxiga shows CV mortality benefit across EF range |
| 30th Aug 2022 7:00 am |
RNS |
Farxiga reduced risk of CV death or worsening HF |
| 25th Aug 2022 7:10 am |
RNS |
Ultomiris approved in Japan for gMG |
| 25th Aug 2022 7:05 am |
RNS |
Tagrisso approved in Japan for early lung cancer |
| 25th Aug 2022 7:00 am |
RNS |
Lynparza approved in Japan for early breast cancer |
| 16th Aug 2022 7:00 am |
RNS |
Lynparza granted FDA priority review for PROpel |
| 15th Aug 2022 7:00 am |
RNS |
Enhertu improved PFS in mBC in DESTINY-Breast02 |
| 12th Aug 2022 7:00 am |
RNS |
Enhertu approved in US for HER2-mutant NSCLC |
| 11th Aug 2022 7:00 am |
RNS |
Acquisition of TeneoTwo completed |
| 8th Aug 2022 7:10 am |
RNS |
Enhertu approved in the US for HER2-low mBC |
| 4th Aug 2022 7:00 am |
RNS |
Lynparza approved in EU for early breast cancer |
| 1st Aug 2022 5:00 pm |
RNS |
Director/PDMR Shareholding |
| 1st Aug 2022 3:05 pm |
RNS |
Director/PDMR Shareholding |
| 1st Aug 2022 3:00 pm |
RNS |
Total Voting Rights |
| 29th Jul 2022 7:01 am |
RNS |
Chair succession |
| 29th Jul 2022 7:00 am |
RNS |
Half-year Report |
| 25th Jul 2022 7:10 am |
RNS |
Tezspire recommended for EU approval in asthma |
| 25th Jul 2022 7:05 am |
RNS |
Ultomiris recommended for EU approval for gMG |
| 25th Jul 2022 7:00 am |
RNS |
Enhertu granted Priority Review for HER2-low mBC |
| 19th Jul 2022 7:00 am |
RNS |
Enhertu approved in EU for HER2-positive mBC |
| 5th Jul 2022 7:00 am |
RNS |
AstraZeneca to acquire TeneoTwo and T cell engager |
| 1st Jul 2022 3:00 pm |
RNS |
Total Voting Rights |
| 30th Jun 2022 7:00 am |
RNS |
Imfinzi improved pCR in resectable lung cancer |
| 27th Jun 2022 7:05 am |
RNS |
Enhertu recommended for breast cancer EU approval |
| 27th Jun 2022 7:00 am |
RNS |
Lynparza recommended in EU for early breast cancer |
| 21st Jun 2022 7:00 am |
RNS |
Eplontersen Ph III trial met co-primary endpoints |
| 6th Jun 2022 7:00 am |
RNS |
Enhertu efficacy results in HER2-low breast cancer |
| 1st Jun 2022 3:00 pm |
RNS |
Block listing Interim Review |
| 1st Jun 2022 3:00 pm |
RNS |
Total Voting Rights |
| 20th May 2022 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 9th May 2022 1:00 pm |
RNS |
Appointment of joint corporate brokers |
| 6th May 2022 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 5th May 2022 7:10 am |
RNS |
Enhertu approved in US for 2L HER2+ breast cancer |
| 5th May 2022 7:05 am |
RNS |
Farxiga HFpEF Phase III trial met primary endpoint |
| 5th May 2022 7:00 am |
RNS |
Ultomiris NMOSD Ph. III trial met primary endpoint |
